CLNN

In January 2026, Clene announced an oversubscribed registered direct offering of over $28 million, priced above market. In March 2026, Clene reported its full-year 2025 financial results, with a net loss of $26.2 million and cash and cash equivalents of $5.2 million as of December 31, 2025, and announced an upcoming Type C meeting with the FDA to discuss biomarker and survival data for CNM-Au8 in ALS. In May 2026, Clene announced a $7 million underwritten offering of common stock and received positive feedback from the FDA regarding the potential for an accelerated approval pathway for CNM-Au8 in ALS, leading to a stock increase. As of May 5, 2026, the share price was $6.58, representing an increase of 130.88% over the past year.